Starton Therapeutics Inc. (“Starton” or the “Company”), a clinical-stage biotechnology company transforming standard-of-care therapies with proprietary dermal technologies, announced today that the ...

BRISBANE, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-class i targeted and immune-mediated ...

Treatment resistance and relapse in the most common type of lung cancer can be traced to a protein called agrin, according to ...

Led by a team of distinguished toxicology experts, TriApex was thrilled to take part in this prestigious meeting, engaging in ...

Full abstract details including title and text are currently available to registrants via the AACR online itinerary planner. A copy of the presentation will be available in the Posters and ...

as a bird flu treatment was presented yesterday in a poster at the International Society for Antiviral Research (ICAR 2025), ...

Forward-Looking Statements This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act ... submissions and the timing thereof, trial results, ...

BioAtla is extending its runway beyond key clinical readouts in 1H 2026 by restructuring and realigning resources, which includes a workforce reduction of over 30%. The Company estimates that it will ...

School providers can offer relevant and feasible interventions for some factors that influence life quality for children with asthma.

The results from this study were presented in the late breaking poster at ACR Convergence ... that fall within the scope of Section 174 over five years for research activities conducted in the ...

Among patients with asthma and obesity, about a quarter of encounters include obesity management, according to a poster at the 2025 American Academy of Allergy, Asthma & Immunology/World Allergy ...